A test of blood offered by Instant viral discrimination for three major viruses received the CE mark.

Pleasanton, California, may of 2011. Roche (SIX: RO, ROG;) OTCQX: RHHBY) announced last Monday that the cobas TaqScreen r test MPX, version 2.0 for use in the system cobas s 201, already available in Europe estácomercialmente

This latest version of the test widely used (R) cobas TaqScreen MPX provides an increase in the sensitivity and is the only commercially available test that provides a simultaneous resolution of viral objective in the automated system, eliminating the need for more tests, with the time that brings about positive units.

This test is a qualitative test in vitro for the direct detection of the virus of human immunodeficiency type 1 group M RNA, HIV-1 Group O RNA, HIV type 2 (HIV-2) RNA, hepatitis C (HCV) RNA virus and hepatitis B (HBV) DNA in human plasma virus (HIV-1). It is provided for the use of the test for show control of donations of blood components complete human and of blood components, including source plasma.

“Roche is the market leader worldwide in sites of donations with tests and tests”, said Paul Brown, responsible for Roche Molecular Diagnostics, the business area of Roche has developed the test. “To develop continuously innovative products are improving the highest level of safety of blood for patients and the effectiveness of the centres of blood.” “This test brings us a step closer to achieving these objectives”.

As a result of the process of Roche global control of the viral genome databases to track the changes that might occur in the viral sequences, trial has reformulated in order to include all recent viral sequences that are possible, increasing the range of the viral targets including.

The cobas TaqScreen r test MPX, v2.0 also offers an efficiency increase in blood centers to eliminate the need for some evidence of viral discrimination, reducing the volume of required samples and the delivery time of the testing of donor. To use the technology in real-time from multiple PCR tinctures, results are detected simultaneously and discriminate HIV, HCV and HBV for specimens individual, eliminating the need for discriminatory test additional time attendant and other commercially available tests.

The test works within the fully automated cobas s 201, which is designed to enhance the effectiveness of prosecution in a modular design with ready to use reagents. Many tinctures technology allows the detection of signals in four separate channels, providing simultaneous control of three viral targets (HIV, HCV and HBV) as well as an internal control of all processes.

In addition to HIV, HCV and HBV, the menu system-cobas s 201 includes tests for the virus in the Western Nile, parvovirus B19 (B19V) and virus hepatitis A (HAV) (2). All control of blood of Roche test based on technology of acid nucleic (NAT), which offers a primary detection of virus from traditional serology tests. System cobas s 201 offers NAT more thorough test available within a single platform automated menu.

On the control of blood and plasma Roche

Roche is leader in the global market for control of blood and plasma NAT, which is estimated to have a value of nearly 800 million Swiss francs. Nucleic acid-based tests enable the primary detection of viral infections with conventional antibody or Antigen tests. Trials of nucleic acids in real time based on PCR Roche used since 1998 for controlling blood and plasma products. There are currently more than 250 blood banks in the world that use the automated cobas s 201 Roche.

Genentech, United States, is a complete affiliate member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan.

(1) this product has not received approval or available for use in United States.

(2) The double test for B19V and hav been completed according to the FDA through a Drug Master File. It is available for laboratories of United States that meet the specific demands of the FDA.